Patrick G. Harran
Gründer bei Joyant Pharmaceuticals, Inc.
Profil
Patrick G.
Harran is the founder of Joyant Pharmaceuticals, Inc. (founded in 2004) and Diazon Pharmaceuticals, Inc. (founded in 2013).
Currently, he is a Member at Alfred P.
Sloan Foundation.
Previously, he worked as a Professor at The University of Texas at Austin.
He received his doctorate degree from Yale University in 1995 and his undergraduate degree from Skidmore College.
Aktive Positionen von Patrick G. Harran
Unternehmen | Position | Beginn |
---|---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Gründer | 16.04.2010 |
Alfred P. Sloan Foundation
Alfred P. Sloan Foundation Miscellaneous Commercial ServicesCommercial Services Alfred P Sloan Foundation operates a non-profit organization. Its programs and interests are divided into five main areas as science & technology, standard of living & economic performance, education &careers in science & technology, selected national issues and the civic program. The foundation was established in 1934 and is headquartered in New York | Corporate Officer/Principal | 20.04.2010 |
Ehemalige bekannte Positionen von Patrick G. Harran
Unternehmen | Position | Ende |
---|---|---|
Diazon Pharmaceuticals, Inc.
Diazon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diazon Pharmaceuticals, Inc. engages in the development of the onco-therapeutic DZ-2384 that targets a proven therapeutic pathway in oncology. The company was founded by Anne Roulston, Gordon Shore and Patrick Harran in 2013 and is headquartered in Montreal, Canada. | Gründer | - |
The University of Texas at Austin | Corporate Officer/Principal | - |
Ausbildung von Patrick G. Harran
Yale University | Doctorate Degree |
Skidmore College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
Alfred P. Sloan Foundation
Alfred P. Sloan Foundation Miscellaneous Commercial ServicesCommercial Services Alfred P Sloan Foundation operates a non-profit organization. Its programs and interests are divided into five main areas as science & technology, standard of living & economic performance, education &careers in science & technology, selected national issues and the civic program. The foundation was established in 1934 and is headquartered in New York | Commercial Services |
Diazon Pharmaceuticals, Inc.
Diazon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diazon Pharmaceuticals, Inc. engages in the development of the onco-therapeutic DZ-2384 that targets a proven therapeutic pathway in oncology. The company was founded by Anne Roulston, Gordon Shore and Patrick Harran in 2013 and is headquartered in Montreal, Canada. | Health Technology |